Updated Results from the Phase III ALEX Trial: Embracing Hazard Ratios
By D. Ross Camidge, MD, and Mary W. Redman, PhD
Posted: August 2018
Updates of the primary analysis of the phase III ALEX trial were presented...
Lorlatinib in ROS1-Positive NSCLC: A Review of Recent Data
By Ben Solomon, MBBS, PhD, FRACP
Posted: August 19, 2020
ROS1 rearrangements are found in 1% to 2% of patients with NSCLC. They tend to occur...
ALK Testing in Europe
By Enriqueta Felip, MD, PhD
Posted: February 2018
ALK-directed TKIs are effective first- and second-line therapies in patients with ALK rearrangements. Testing of all patients with...
Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer...
By Cynthia L. Kryder, MS, CCC-Sp
Editor Note: IASLC Lung Cancer News is pleased to provide the following overview, which is followed by expert commentary...
Osimertinib: A New Option in Non-Small Cell Lung Cancer – Q&A with David R....
By Erik J. MacLaren, PhD
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), received FDA approval in November 2015 for use...
Alectinib and ALK-Positive Non-Small Cell Lung Cancer – Q&A with Alice T. Shaw, MD,...
By Erik J. MacLaren, PhD
Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that was recently approved in the US as a second- line...
Benefit of EGFR Mutation Analysis from Plasma Cell-Free DNA for Treatment of Advanced Non-Small...
By Tony S. K. Mok, BMSc, MD, FRCPC
Patients must first be identified as having an epidermal growth factor receptor (EGFR) mutation before they can...
The Lung Master Protocol (Lung-MAP)
By Vassiliki A. Papadimitrakopoulou, MD
Lung-MAP (S1400), is a unique master multi-study protocol that incorporates genomic testing of tumors through a next-generation sequencing (NGS) platform...
Q & A with Yi-Long Wu, MD
What is the current standard of care in the adjuvant setting post-resection of high-risk NSCLC in your practice or nationally?
Posted: October 2017
Current Chinese Lung...
Clinical Labeling in Medicinal Products: An Interview With Dr. David Planchard About the Effects...
Posted: June 2017
By David Planchard, MD, PhD
What was the rationale for conducting clinical research in BRAF mutationpositive NSCLC?
Recently, progress has been made in characterization...
